Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/10/2021 06/11/2021 06/15/2021 06/16/2021 06/17/2021 Date
73 72.96 71.88 70.81 71.15 Last
61779040 44820870 43843800 28037760 23354800 Volume
+4.10% -0.05% -1.48% -1.49% +0.48% Change
Financials
Sales 2021 34 784 M 5 395 M 5 395 M
Net income 2021 7 675 M 1 190 M 1 190 M
Net cash position 2021 19 807 M 3 072 M 3 072 M
P/E ratio 2021 58,7x
Yield 2021 0,28%
Sales 2022 41 348 M 6 413 M 6 413 M
Net income 2022 9 359 M 1 452 M 1 452 M
Net cash position 2022 25 214 M 3 911 M 3 911 M
P/E ratio 2022 48,3x
Yield 2022 0,33%
Capitalization 453 B 70 289 M 70 295 M
EV / Sales 2021 12,5x
EV / Sales 2022 10,4x
Nbr of Employees 28 903
Free-Float 46,3%
More Financials
Company
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases. 
Sector
Pharmaceuticals
Calendar
09/02Earnings Release
More about the company
Ratings of Jiangsu Hengrui Medicine Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
05/03Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High
DJ
03/15EXCLUSIVE : China's JD.com in talks to buy stake worth $1.5 billion in brokerage..
RE
02/10MARKET CHATTER : Jiangsu Hengrui Medicine to Invest $20 Million in Drug Research..
MT
2020Drugmakers agree to halve prices to get on China state insurance list
RE
2020JIANGSU HENGRUI MEDICINEá : Nine-Month Net Profit Rose 14%
DJ
2020Stymied at home, Korea's mom and pop investors charge into China tech stocks
RE
2020Stymied at home, Korea's mom and pop investors charge into China tech stocks
RE
2020THERMO FISHER SCIENTIFICá : Signs Companion Diagnostic Agreement with Hengrui Th..
AQ
2020JIANGSU HENGRUI MEDICINE CO., LTD. : Ex-dividend day for final dividend
FA
2020JIANGSU HENGRUI MEDICINE CO., LTD. : 20% Stock Dividend
FA
2020How a virus impacts the economy and markets
RE
2019JIANGSU HENGRUI MEDICINEá : Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine..
BU
2019JIANGSU HENGRUI MEDICINE CO. : 20% Stock Dividend
FA
2019JIANGSU HENGRUI MEDICINE CO. : Ex-dividend day for final dividend
FA
2018JIANGSU HENGRUI MEDICINE CO LTD : Ex-dividend day for final dividend
FA
More news
News in other languages on JIANGSU HENGRUI MEDICINE CO., LTD.
03/12SINOLINK SECURITIESá : JD.com négocie son entrée au capital du courtier Sinolink
2020VALEURS MOYENNES DU BTPá : Après l'arrêt total, la reprise des chantiers reste c..
More news
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | 600276 | CNE0000014W7 | MarketScreener
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 87,03 CNY
Last Close Price 71,15 CNY
Spread / Highest target 49,9%
Spread / Average Target 22,3%
Spread / Lowest Target -9,81%
EPS Revisions
Managers and Directors
NameTitle
Yun Shu Zhou Chairman & General Manager
Song Zhou Chief Financial Officer
Wei Dong Chairman-Supervisory Board
Shuang Xue Independent Director
Qian Wang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-23.40%70 505
JOHNSON & JOHNSON4.48%433 009
ROCHE HOLDING AG12.33%333 736
PFIZER, INC.6.76%219 989
NOVARTIS AG1.83%212 691
ABBVIE INC.7.82%204 052